Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Effect of tenofovir on nucleotidases and cytokines in HIV-1 target cells.

Biswas N, Rodriguez-Garcia M, Crist SG, Shen Z, Bodwell JE, Fahey JV, Wira CR.

PLoS One. 2013 Oct 25;8(10):e78814. doi: 10.1371/journal.pone.0078814. eCollection 2013.

2.

Effects of tenofovir on cytokines and nucleotidases in HIV-1 target cells and the mucosal tissue environment in the female reproductive tract.

Biswas N, Rodriguez-Garcia M, Shen Z, Crist SG, Bodwell JE, Fahey JV, Wira CR.

Antimicrob Agents Chemother. 2014 Nov;58(11):6444-53. doi: 10.1128/AAC.03270-14. Epub 2014 Aug 18.

3.

Sex hormones regulate tenofovir-diphosphate in female reproductive tract cells in culture.

Shen Z, Fahey JV, Bodwell JE, Rodriguez-Garcia M, Kashuba AD, Wira CR.

PLoS One. 2014 Jun 30;9(6):e100863. doi: 10.1371/journal.pone.0100863. eCollection 2014.

4.

Metabolism and antiretroviral activity of tenofovir alafenamide in CD4+ T-cells and macrophages from demographically diverse donors.

Bam RA, Birkus G, Babusis D, Cihlar T, Yant SR.

Antivir Ther. 2014;19(7):669-77. doi: 10.3851/IMP2767. Epub 2014 Mar 14.

PMID:
24625459
5.

Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.

Lanier ER, Ptak RG, Lampert BM, Keilholz L, Hartman T, Buckheit RW Jr, Mankowski MK, Osterling MC, Almond MR, Painter GR.

Antimicrob Agents Chemother. 2010 Jul;54(7):2901-9. doi: 10.1128/AAC.00068-10. Epub 2010 May 3.

6.
7.

IL-15 delays suppression and fails to promote immune reconstitution in virally suppressed chronically SIV-infected macaques.

Lugli E, Mueller YM, Lewis MG, Villinger F, Katsikis PD, Roederer M.

Blood. 2011 Sep 1;118(9):2520-9. doi: 10.1182/blood-2011-05-351155. Epub 2011 Jul 14.

8.

Antiviral and immunological effects of tenofovir microbicide in vaginal herpes simplex virus 2 infection.

Vibholm L, Reinert LS, Søgaard OS, Paludan SR, Østergaard L, Tolstrup M, Melchjorsen J.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1404-11. doi: 10.1089/AID.2012.0078. Epub 2012 Sep 25.

PMID:
22867119
9.

Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.

Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, Ham C, Heeney J, Rezk N, Kashuba A, Anton P, McGowan I, Shattock R.

PLoS Med. 2008 Aug 5;5(8):e157; discussion e157. doi: 10.1371/journal.pmed.0050157.

10.

Decreased stimulation of CD4+ T cell proliferation and IL-2 production by highly enriched populations of HIV-infected dendritic cells.

Kawamura T, Gatanaga H, Borris DL, Connors M, Mitsuya H, Blauvelt A.

J Immunol. 2003 Apr 15;170(8):4260-6.

11.

Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.

Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, Cohen MS, Kashuba AD.

Sci Transl Med. 2011 Dec 7;3(112):112re4. doi: 10.1126/scitranslmed.3003174.

12.

Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovir.

Kulkarni R, Feng JY, Miller MD, White KL.

Antiviral Res. 2014 Jan;101:131-5. doi: 10.1016/j.antiviral.2013.11.010. Epub 2013 Nov 28.

PMID:
24291780
13.

Prostate carcinoma cells LNCaP and glucan cooperate in induction of cytokine synthesis by dendritic cells: effect on natural killer cells and CD4+ lymphocytes activation.

Donini M, Marongiu L, Fontana E, Dusi S.

Prostate. 2012 Apr;72(5):566-76. doi: 10.1002/pros.21460. Epub 2011 Jul 27.

PMID:
21796650
14.

Estradiol regulation of nucleotidases in female reproductive tract epithelial cells and fibroblasts.

Shen Z, Fahey JV, Bodwell JE, Rodriguez-Garcia M, Rossoll RM, Crist SG, Patel MV, Wira CR.

PLoS One. 2013 Jul 25;8(7):e69854. doi: 10.1371/journal.pone.0069854. Print 2013.

15.

Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention.

Dezzutti CS, Shetler C, Mahalingam A, Ugaonkar SR, Gwozdz G, Buckheit KW, Buckheit RW Jr.

Antiviral Res. 2012 Nov;96(2):221-5. doi: 10.1016/j.antiviral.2012.08.004. Epub 2012 Aug 23.

16.

Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine.

Ray AS, Myrick F, Vela JE, Olson LY, Eisenberg EJ, Borroto-Esodo K, Miller MD, Fridland A.

Antivir Ther. 2005;10(3):451-7.

PMID:
15918336
17.

Interactions between tenofovir and nevirapine in CD4+ T cells and monocyte-derived macrophages restrict their intracellular accumulation.

Liptrott NJ, Curley P, Moss D, Back DJ, Khoo SH, Owen A.

J Antimicrob Chemother. 2013 Nov;68(11):2545-9. doi: 10.1093/jac/dkt225. Epub 2013 Jun 21.

19.

Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis.

Chaowanachan T, Krogstad E, Ball C, Woodrow KA.

PLoS One. 2013 Apr 22;8(4):e61416. doi: 10.1371/journal.pone.0061416. Print 2013.

20.

Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue.

Louissaint NA, Cao YJ, Skipper PL, Liberman RG, Tannenbaum SR, Nimmagadda S, Anderson JR, Everts S, Bakshi R, Fuchs EJ, Hendrix CW.

AIDS Res Hum Retroviruses. 2013 Nov;29(11):1443-50. doi: 10.1089/AID.2013.0044. Epub 2013 May 29.

Supplemental Content

Support Center